Format

Send to

Choose Destination
Medicine (Baltimore). 2019 Jan;98(2):e14072. doi: 10.1097/MD.0000000000014072.

Malignant perivascular epithelioid cell tumor in the female genital tract: Preferred reporting items for systematic reviews and meta-analyses.

Liu CH1,2,3, Chao WT1,3,4, Lin SC2,5,6, Lau HY1,3,7, Wu HH1,3,8, Wang PH1,2,3,9.

Author information

1
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital.
2
Institute of Clinical Medicine, National Yang-Ming University.
3
Department of Obstetrics and Gynecology, National Yang-Ming University.
4
School of Medicine, Fu-Jen Catholic University, New Taipei City.
5
Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei.
6
School of Medicine, National Defense Medical Center, Taipei.
7
School of Medicine, China Medical University, Taichung.
8
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
9
Department of Medical Research, China Medical University Hospital, Taichung.

Abstract

BACKGROUND:

Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal tumor, located at various anatomic sites, including the female genital tract. This study aimed to evaluate the clinicopathological characteristics of patients with PEComa arising from the female genital tract.

METHODS:

A retrospective study was conducted in Taipei Veterans General Hospital (Taipei VGH) between 2008 and 2018. All published English cases based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement were also included in the current review.

RESULTS:

A total of 114 women from PRISMA and 3 women from Taipei VGH were identified. The uterus was the most commonly involved site (82/114, 71.9%), followed by the cervix (12/114, 10.5%). Immunohistochemical staining showed that nearly all gynecological PEComas were positive for human melanoma black 45 (113/114, 99.1%). More than half of the gynecological PEComas were immunoreactive for desmin (50/85, 58.8%). Multi-modality treatment, including surgery and mammalian target of rapamycin (mTOR) inhibitors as targeted therapy, provided long-term disease-free survival (cure rate ranging from 50% to 100%, based on the different anatomic sites of the female genital tract).

CONCLUSION:

Multi-modality treatment, including cytoreductive surgery and mTOR inhibitors with/without chemotherapy and/or radiation, should be considered for the management of women with PEComas in the genital tract.

PMID:
30633211
PMCID:
PMC6336598
DOI:
10.1097/MD.0000000000014072
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center